Chemotherapy-induced peripheral neuropathy is one of the fastest-growing segments in the peripheral neuropathy market. As cancer diagnosis and treatment improve, more people are living longer after chemotherapy and may require ongoing support for treatment-related nerve symptoms. 1158

Chemotherapy-induced neuropathy can affect sensation, movement, balance, and daily function. Some patients experience numbness, tingling, pain, or weakness in the hands and feet during or after cancer treatment. The type and severity of symptoms can vary based on the medicine used, dose, treatment duration, and individual health factors.

Oncology teams are increasingly focused on survivorship care. This includes symptom monitoring, rehabilitation, pain management, fall prevention, occupational therapy, and coordination with neurology or pain specialists when needed.

Non-pharmacological therapies are gaining attention because patients may benefit from exercise, physiotherapy, counseling, mobility training, and supportive-care programs in addition to medical treatment. Research into neuroprotective therapies and regenerative medicine may also influence the market in the future.

As cancer care becomes more personalized, neuropathy management is likely to become a more important part of patient experience and long-term quality-of-life planning.

Read more: Peripheral Neuropathy Market 1158

FAQs

Q1. What is chemotherapy-induced peripheral neuropathy?
It is nerve damage or nerve-related symptoms associated with some chemotherapy treatments.

Q2. Why is this segment growing?
Improved cancer survival means more patients may need long-term support for treatment-related side effects.

Tags: chemotherapy-induced neuropathy, cancer survivorship, neuropathic pain, oncology supportive care, rehabilitation therapy